Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | TP53 del |
Gene Variant Detail | |
Relevant Treatment Approaches |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02518555 | Phase II | Ibrutinib | Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Active, not recruiting | USA | 0 |
NCT05275439 | Phase I | Azacitidine + SL-172154 + Venetoclax Azacitidine + SL-172154 SL-172154 | Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML | Active, not recruiting | USA | GBR | CAN | 0 |
NCT03661307 | Phase Ib/II | Decitabine + Quizartinib + Venetoclax | Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT04155840 | Phase II | Bendamustine + Copanlisib + Rituximab | Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Terminated | USA | 0 |
NCT03144804 | Phase II | Lamivudine | A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT04190550 | Phase I | Cytarabine + Idarubicin + KRT-232 | Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT04435691 | Phase Ib/II | Azacitidine + Hu5F9-G4 + Venetoclax | Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |